Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

  • This share is currently suspended. It was suspended at a price of 1.2699
  • There is currently no data for ONC

Director/PDMR Shareholding

11 Nov 2024 11:15

RNS Number : 7323L
Oncimmune Holdings PLC
11 November 2024
Β 

For immediate release

Β 

Β 

Β 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Director/PDMR Shareholding

Β 

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company providing research services to the pharmaceutical and biotechnology industries to enable the delivery of precision medicine, announces the acquisition of Subscription Shares by certain board members, and waiver and issue of share options to certain Persons Discharging Managerial Responsibilities pursuant to the Fundraising, as detailed in the Company's announcement dated 18 October 2024 (the "Fundraising Announcement"). A summary of the subscribing Directors' shareholdings are as follows:

Β 

Subscription for ordinary shares

Β 

PDMR

Previous holding of Ordinary Shares

Number of Subscription Shares purchased

Β 

Resultant shareholding

Resulting % of Enlarged Share Capital

Alistair Macdonald

55,555

100,000

155,555

0.14

Martin Gouldstone

36,023

66,667

102,690

0.09

John Goold

1,150,000

333,333

1,483,333

1.33

Β 

Waiver of options

PDMR

Number of options waived

Date of grant of options waived

Β 

Exercise price of options waived

Resulting number of options held

Martin Gouldstone

589,971

7 November 2023

Β£0.1695

0

Martin Hudson

105,263

8 December 2023

Β£0.266

0

Β 

Grant of options

PDMR

Number of options granted

Exercise price

Β 

% of Enlarged Share Capital

Martin Gouldstone

5,588,661

Β£0.15

5%

Martin Hudson

3,353,197

Β£0.15

3%

Β 

The new options are subject to performance conditions relating to the Company's EBITDA and share price performance, further detail of which is set out in the Fundraising Announcement.

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the announcement of the Fundraising made by the Company on 18 October 2024.

Β 

For further information:

Β 

Oncimmune Holdings plc

contact@oncimmune.com

Β 

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)Β 

Nigel Birks (Life Science Specialist Sales)

Ondraya Swanson (ECM)

+44 (0) 20 7220 0500

Β 

Zeus (Joint Broker)

Dominic King, Dan Bate

+44 (0)20 3829 5000

Β 

The notifications set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1.Β 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Alistair Macdonald

1.Β 

Reason for the notification

a)

Position/status:

Chairman

b)

Initial notification/Amendment:

Initial notification

2.Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3.Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Purchase of new ordinary shares

c)

Price(s) and volume(s):

Β 

Price(s)

Volume(s)

15.0 pence

100,000

Β 

d)

Aggregated information:

Β·Β Aggregated volume:

Β·Β Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

23 October 2024

f)

Place of the transaction:

AIM, London Stock Exchange (XLON)

Β Β 

1.Β 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Martin Gouldstone

1.Β 

Reason for the notification

a)

Position/status:

Chief Executive Officer

b)

Initial notification/Amendment:

Initial notification

2.Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3.Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Purchase of new ordinary shares

c)

Price(s) and volume(s):

Β 

Price(s)

Volume(s)

15.0 pence

66,667

Β 

d)

Aggregated information:

Β·Β Aggregated volume:

Β·Β Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

23 October 2024

f)

Place of the transaction:

AIM, London Stock Exchange (XLON)

Β 

1.Β 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

John Goold

1.Β 

Reason for the notification

a)

Position/status:

Non-Executive Director

b)

Initial notification/Amendment:

Initial notification

2.Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3.Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Purchase of new ordinary shares

c)

Price(s) and volume(s):

Β 

Price(s)

Volume(s)

15.0 pence

333,333

Β 

d)

Aggregated information:

Β·Β Aggregated volume:

Β·Β Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

23 October 2024

f)

Place of the transaction:

AIM, London Stock Exchange (XLON)

Β 

1.Β 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Martin Gouldstone

1.Β 

Reason for the notification

a)

Position/status:

Chief Executive Officer

b)

Initial notification/Amendment:

Initial notification

2.Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3.Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Waiver of options

c)

Price(s) and volume(s):

Β 

Price(s)

Volume(s)

16.95 pence

589,971

Β 

d)

Aggregated information:

Β·Β Aggregated volume:

Β·Β Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

8 November 2024

f)

Place of the transaction:

Outside a trading venue

Β 

Β 

1.Β 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Martin Hudson

1.Β 

Reason for the notification

a)

Position/status:

Finance Director

b)

Initial notification/Amendment:

Initial notification

2.Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3.Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Waiver of options

c)

Price(s) and volume(s):

Β 

Price(s)

Volume(s)

26.6 pence

105,263

Β 

d)

Aggregated information:

Β·Β Aggregated volume:

Β·Β Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

8 November 2024

f)

Place of the transaction:

Outside a trading venue

Β 

1.Β 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Martin Gouldstone

1.Β 

Reason for the notification

a)

Position/status:

Chief Executive Officer

b)

Initial notification/Amendment:

Initial notification

2.Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3.Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Grant of options

c)

Price(s) and volume(s):

Β 

Price(s)

Volume(s)

15 pence

5,588,661

Β 

d)

Aggregated information:

Β·Β Aggregated volume:

Β·Β Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

8 November 2024

f)

Place of the transaction:

Outside a trading venue

Β 

Β 

1.Β 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Martin Hudson

1.Β 

Reason for the notification

a)

Position/status:

Finance Director

b)

Initial notification/Amendment:

Initial notification

2.Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Oncimmune Holdings plc

b)

LEI:

213800HCYIWT6YPI1I02

3.Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00BYQ94H38

b)

Nature of the transaction:

Grant of options

c)

Price(s) and volume(s):

Β 

Price(s)

Volume(s)

15 pence

3,353,197

Β 

d)

Aggregated information:

Β·Β Aggregated volume:

Β·Β Aggregated Price:

Single transaction as in 3 c) above

e)

Date of the transaction:

8 November 2024

f)

Place of the transaction:

Outside a trading venue

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHFFLFFZFLFFBE
Date   Source Headline
2nd Feb 20247:00 amRNSNotice of AGM
11th Dec 20233:12 pmRNSDirector/PDMR Shareholding
8th Dec 20232:31 pmRNSGrant of Options and PDMR Dealing
30th Nov 20237:00 amRNSProgress against Strategy
10th Nov 202310:14 amRNSHolding(s) in Company
7th Nov 20234:11 pmRNSGrant of Options and PDMR Dealing
19th Oct 20237:00 amRNSInvestor Presentation via Investor Meet Company
12th Oct 20237:00 amRNSUpdate on Strategy & Changes to the Board
1st Aug 20237:00 amRNSBoard Changes
14th Jul 20232:00 pmRNSCorrected unaudited interim results to 31 May 2022
12th Jul 20237:00 amRNSAppointment of new leadership team & board changes
26th Jun 202311:10 amRNSChange of registered office
23rd Jun 20237:00 amRNSTransition of Executive Leadership
15th Jun 20235:16 pmRNSCorrection to interim results
13th Jun 20237:45 amRNSHolding(s) in Company
5th Jun 20234:02 pmRNSDirector/PDMR Shareholding
31st May 20237:00 amRNSInterim Results
22nd May 20237:00 amRNSSale of Oncimmune Limited to Freenome
3rd Apr 20234:38 pmRNSHolding(s) in Company
27th Mar 202311:07 amRNSResult of GM
3rd Mar 20237:00 amRNSPosting of Annual Report and Notice of GM
27th Feb 20232:36 pmRNSResult of AGM
27th Feb 20237:00 amRNSFinal Results
23rd Feb 20237:00 amRNSAppointment of Joint Broker
17th Feb 20237:00 amRNSSiemens Healthineers Collaboration
3rd Feb 202311:50 amRNSNotice of AGM
31st Jan 20237:00 amRNSNotice of Results
13th Jan 20237:00 amRNSAppointment of Non-Executive Director
20th Dec 20227:00 amRNSImmunoINSIGHTS Trading Update
19th Dec 20221:35 pmRNSDirector/PDMR Shareholding
14th Dec 20222:00 pmRNSResult of Capital Raising
9th Dec 20221:30 pmRNSExtension of Capital Raising
7th Dec 20222:00 pmRNSProposed Placing and Subscription
4th Nov 20224:16 pmRNSGrant of Options and PDMR Dealing
21st Sep 20222:16 pmRNSPDMR Dealing
21st Sep 20227:00 amRNSUnaudited results for the 12 months to 31 May 2022
30th Aug 20223:53 pmRNSRevised Notice of Results
15th Aug 20222:06 pmRNSHolding(s) in Company
8th Aug 202211:55 amRNSHolding(s) in Company
15th Jul 202210:44 amRNSHolding(s) in Company
13th Jul 20227:00 amRNSGrant of Options and PDMR Dealing
8th Jul 20227:00 amRNSBoard Changes and Trading Update
20th Jun 20222:19 pmRNSHolding(s) in Company
16th Jun 20229:59 amRNSHolding(s) in Company
7th Jun 202210:20 amRNSHolding(s) in Company
6th Jun 20229:30 amRNSHolding(s) in Company
1st Jun 20228:18 amRNSHolding(s) in Company
31st May 202212:41 pmRNSHolding(s) in Company
26th May 20229:57 amRNSHolding(s) in Company
23rd May 20224:27 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.